Alimera Sciences Inc ALIM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.59
- Day Range
- $3.49–3.70
- 52-Week Range
- $1.56–4.38
- Bid/Ask
- $3.00 / $3.95
- Market Cap
- $190.05 Mil
- Volume/Avg
- 7,722 / 76,485
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.15
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 158
- Website
- https://www.alimerasciences.com
Valuation
|
Metric
|
ALIM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.55 |
Price/Sales | 1.15 |
Price/Cash Flow | 60.25 |
Price/Earnings
ALIM
Financial Strength
|
Metric
|
ALIM
|
|---|---|
Quick Ratio | 2.13 |
Current Ratio | 2.39 |
Interest Coverage | −0.97 |
Quick Ratio
ALIM
Profitability
|
Metric
|
ALIM
|
|---|---|
Return on Assets (Normalized) | −11.50% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −6.09% |
Return on Assets
ALIM
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Ftmkrnvcr | Wqdyhq | $70.9 Bil | |
ZTS
| Zoetis Inc Class A | Bkhfptqty | Dwmm | $68.9 Bil | |
HLN
| Haleon PLC ADR | Zyvkklyn | Zzvn | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Sjngzfbr | Smkzf | $14.7 Bil | |
VTRS
| Viatris Inc | Shkpysbr | Zrtb | $13.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Ljmmcrljd | Sqsy | $11.9 Bil | |
CTLT
| Catalent Inc | Ghnpwcfqd | Vgjmfd | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Cqpvgwyt | Vxv | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Dkltxtj | Jwryv | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Tnlgzrwq | Crdykn | $3.5 Bil |